EGFR and non-small cell lung carcinoma: Gefitinib and afatinib, the first- and second-generation EGFR-TKIs, are used as first-line therapy for advanced NSCLC patients harboring EGFR sensitizing mutations [7] (exon 19 deletion and L858R mutation).